November 28, 2021 23:17 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tripura civic polls counting: BJP leads comfortably, wins 19 wards | Arvind Kejriwal slams critics for taking dig at his Punjab poll promise of monthly 1k transfer to all women | India registers 8,774 new COVID-19 cases amid Omicron variant scare | Maharashtra CID to quiz Param Bir Singh next week | Tripura civic polls counting on, BJP takes early leads, high stakes for TMC

Hong Kong approves persons vaccinated with Covaxin for inbound travel

New Delhi/UNI: Travellers who have received both doses of Covaxin are now eligible for inbound travel to Hong Kong as the country has included the India-made COVID-19 vaccine into its list of approved vaccines.

Bharat Biotech's US partner files request for paediatric use of Covaxin

New Delhi/UNI: Ocugen Inc, Bharat Biotech's partner in the US and Canada for Covaxin, has submitted a request to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the Covid-19 jab for paediatric use.

Chinese vax took longer than COVAXIN to get approval, says WHO

New Delhi/IBNS: Covaxin did not take the longest to get the World Health Organization's (WHO) approval for Emergency Use Listing, according to Chief Scientist Dr Soumya Swaminathan.

Bharat Biotech's COVAXIN gets WHO approval

New Delhi/IBNS: The World Health Organization (WHO) has given emergency use approval to Bharat Biotech's Covaxin, sources said Wednesday, clearing the way for the 'made-in-India' vaccine to get recognised by other nations and Indians inoculated with the shot would no longer need to self-quarantine or face restrictions when going abroad.

Bharat Biotech's Covaxin recommended for use in children below 18 years

New Delhi/IBNS: An expert panel on Tuesday recommended Bharat Biotech's Covaxin to be administered on children between the ages of two and 18.

Decision on Covaxin's clearance next: WHO

New Delhi/IBNS: The World Health Organisation (WHO) on Tuesday said it will announce its decision on clearance of India's indigenously developed Covaxin next week when the UN agency and an independent group of experts meet.

WHO's clearance to Bharat Biotech's Covaxin delayed: Reports

New Delhi/IBNS: The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the COVID vaccine developed in India by pharmaceutical company Bharat Biotech, media reports said.

WHO approval for Covaxin likely by month-end, says Niti Aayog

New Delhi/IBNS: The World Health Organisation's emergency approval for indigenously made Covid-19 jab, Covaxin, can come by the end of September, said Dr VK Paul, chairman of the National Expert Committee on Vaccine Administration, according to media reports.

Bharat Biotech's 1st nasal COVID vaccine gets approval for phase 2 trial

New Delhi/IBNS: Bharat Biotech has received phase 2 human clinical trial nod for its nasal COVID vaccine, called BBV154, the Union Government informed on Friday.

Health Minister Mansukh Mandaviya meets WHO chief scientist to discuss Covaxin approval

New Delhi/IBNS: Union Health Minister Mansukh Mandaviya on Thursday met World Health Organisation (WHO) Chief Scientist Dr Soumya Swaminathan to hold discussion over the global health body's approval for Bharat Biotech's COVID-19 vaccine Covaxin.

Decision on Covaxin's emergency use listing in 4-6 weeks: WHO

New Delhi/IBNS: The World Health Organisation (WHO) will take a decision on emergency use approval for Bharat Biotech's Covaxin in the next four to six weeks, Soumya Swaminathan, the UN health body's chief scientist has said.

India reports 39,796 COVID-19 cases, 723 deaths in 24 hours

New Delhi/IBNS: India, which is recovering from the second wave of COVID-19, on Monday reported over 39,000 new infections besides 723 deaths apparently due to the virus.

Covaxin's efficacy result will help getting WHO's approval : Govt expert body chief

New Delhi/IBNS: India-made Covaxin's recently published result on efficacy will help the vaccine in getting World Health Organisation’s (WHO) emergency approval, the chairperson of National Technical Advisory Group on Immunisation in India (NTAGI), Dr NK Arora said on Saturday.

Covaxin overall 77.8% effective against COVID-19, claims Bharat Biotech

New Delhi/IBNS: Hyderabad-based biotechnology company Bharat Biotech has claimed its anti-COVID-19 vaccine, Covaxin, is 77.8% effective against the deadly virus.

Bharat Biotech says COVAXIN records 77.8 percent effectiveness against COVID-19 

Hyderabad:  Bharat Biotech on Saturday claimed its created COVID-19 vaccine COVAXIN has shown 77.8 per cent effectiveness against the virus.